secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001171843-25-004977
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst Q2 ORLADEYO rev $156.8M (+45% YoY); net income $5.1M vs loss $12.7M
----------------------------------------------------------------------------

- Q2 total revenue $163.4M (+50% YoY); ORLADEYO net rev $156.8M (+45% YoY).
- Operating income $29.8M (up from $8.8M); non-GAAP op income $57.0M (up from $21.9M).
- Net income $5.1M ($0.02 EPS) vs net loss $12.7M ($0.06 loss) in Q2 2024.
- Made additional $50M term debt paydown in July; plans to retire remaining $199M with proceeds from European ORLADEYO sale expected to close early Oct.
- Full-year 2025 ORLADEYO revenue guidance maintained at $580M-$600M; pipeline on track for data in two programs by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004977/0001171843-25-004977-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004977/f8k_080425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004977

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer